1. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. Magnetic iron oxide nanoparticles: Synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2009; 108: 2064-2110.
2. Zhao Z, Zhou Z, Bao J, Wang Z, Chi X, Ni K, Wang R, Chen X, Chen Z, Gao J. Octapod iron oxide nanoparticles as high performance T2 contrast agents for magnetic resonance imaging. Nat Commun. 2013; 4: 2266-2272.
3. Lee H, Shin T-H, Cheon J, Weissleder R, Recent developments in magnetic diagnostic systems, Chem Rev. 2015; 115: 10690-10724.
4. Rinck PA. Magnetic Resonance in Medicine. ABW wissenschaftsverlag, Germany, 2003.
5. Major JL, Meade TJ. Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res. 2009; 42: 893–903.
6. Cabella C, Crich SG, Corpillo D, Barge A, Ghirelli C, Bruno E, Lorusso V, Ugerri F, Aime S. Cellular labeling with Gd (III) chelates: only high thermodynamic stabilities prevent the cells acting as ‘sponges’ of Gd3+ ions. Contrast Med Mol Imag. 2006; 1: 23-29.
7. Idée JM, Port M, Raynal I, Schaefer M, Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging. Fund Clin Pharm. 2006; 20: 563-576.
8. Laurent S, Vander Elst L, Copoix F, Muller RN. Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol. 2001; 36: 115-122.
9. Thomsen H, Morcos S, Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol. 2006; 61: 905-906.
10.Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol. 2006; 16: 2619-2621.
11. Arsalani N, Fattahi H, Laurent S, Burtea C, Vander Elst L, Muller RN. Polyglycerol-grafted superparamagnetic iron oxide nanoparticles: highly efficient MRI contrast agent for liver and kidney imaging and potential scaffold for cellular and molecular imaging. Contrast Med Mol Imag. 2012; 7: 185-194.
12. Arsalani N, Fattahi H, Nazarpoor M. Synthesis and characterization of PVP-functionalized paramagnetic Fe3O4 nanoparticles as an MRI contrast agent. Exp Polym Lett. 2010; 4: 329-338.
13. Li F, Liang Z et al. Dynamically reversible iron oxide nanoparticle assemblies for targeted amplification of T1-weighted magnetic resonance imaging of tumors. Nano Lett. 2019; 8b04411.
14.Su H, Han X, He L, Deng L, Yu K, Jiang H, Wu C, Jia Q, Shan S. Synthesis and characterization of magnetic dextran nanogel doped with iron oxide nanoparticles as magnetic resonance imaging probe. Int J Biol Macromol 2019, 128(1); 768-774.
15. Fattahi H, Laurent S, Liu F, Arsalani N, Vander Elst L, Muller RN. Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics. Nanomedicine (Lond). 2011; 6: 529-544.
16. Wei H, Bruns OT et al. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents. Proc Nat Acad Sci. 2017; 114: 2325-2330.
17. Bao Y, Sherwood J, Sun Z. Magnetic iron oxide nanoparticles as T1 contrast agents for magnetic resonance imaging. J Mat Chem C. 2018; 6: 1280-1290.
18. Kania G, Sternak M, Jasztal A, Chlopicki S, Błażejczyk A, Nasulewicz-Goldeman A, Wietrzyk J, Jasiński K, Skórka T, Zapotoczny S, Nowakowska M. Uptake and bioreactivity of charged chitosan-coated superparamagnetic nanoparticles as promising contrast agents for magnetic resonance imaging. Nanomedicine: NBM. 2018; 14: 131-140.
19. Aires A, Ocampo SM et al. Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology. 2016; 27: 065103.
20. Laurent S, Dutz S, Hafeli UO, Mahmoudi M. Magnetic fluid hyperthermia: Focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci. 2011; 1669: 8-23.
21. Kaushik A, Khan R, Solankia PR, Pandey P, Alam J, Ahmad S, Malhotra BD. Iron oxide nanoparticles–chitosan composite based glucose biosensor. Biosens Bioelectron. 2008; 24: 676-683.
22. Fatima H, Kim KS. Magnetic nanoparticles for bioseparation. Korean J Chem Eng. 2017; 34(3): 589-599.
23. Lacava LM, Lacava ZG, Silva MF, Silva O, Chaves SB, Azevedo RB, Pelegrini F, Gansau C, Buske N, Sabolovic D, Morais PC. Magnetic resonance of a dextran-coated magnetic fluid intravenously administered in mice. Biophys J. 2001; 80: 2483–2486.
24. Lin H, Watanabe Y, Kimura M, Hanabusa K, Shirai H, Preparation of magnetic poly(vinyl alcohol) (PVA) materials by in situ synthesis of magnetite in a PVA matrix. J Appl Polym Sci. 2003; 87: 1239–1247.
25. Cheraghipour E, Javadpour S, Mehdizadeh AR. Citrate-capped superparamagnetic iron oxide nanoparticles used for hyperthermia therapy. J Biomed Sci Eng. 2012; 5: 715-719.
26.Iqbal MZ, Ma X, Chen T, Zhang L, Ren W, Xiang L, Wu A. Silica-coated superparamagnetic iron oxide nanoparticles (SPIONs): a new type contrast agent of T1 magnetic resonance imaging (MRI). J Mater Chem B. 2015; 3: 5172-5181.
27. Garrec DL, Gori S, Luo L, Lessard D, Smith DC, Yessine MA, Ranger M, Leroux JC. Poly (N-vinylnpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: In vitro and in vivo evaluation. J Control Release. 2004; 99: 83–101.
28.Lee H, Lee E, Kim DK, Jang NK, Jeong YY, Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc. 2006; 128: 7383–7389.
29. Kohler N, Fryxell GE, Zhang M. A bifunctional poly (ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc. 2004; 126: 7206 –7211.
30. Feng B, Hong RY, Wang LS, Guo L, Li HZ, Ding J, Zheng Y, Wei DG. Synthesis of Fe3O4/APTES/PEG diacid functionalized magnetic nanoparticles for MR imaging. Colloid Surf A: Physicochem Eng Aspec. 2008; 328: 52–59.
31. Nazarpoor M. The effect of repetition time on the maximum linear relationship between contrast agent concentration and signal intensity on T1-weighted image using inversion recovery (IR) sequence. Iran J Radiol. 2009; 6: 247-252.
32. Nazarpoor M, Poureisa M, Daghighi MH. Effect of echo time on the maximum relationship between contrast agent concentration and signal intensity using FLAIR sequence. Iran J Med Phys. 2013; 10: 59-67.
33. Nazarpoor M. Effects of inversion and saturation times on relationships between contrast agent concentrations and signal intensities of T1-weighted magnetic resonance images. Radiol Phys Technol. 2010; 3: 120-126.
34. Nazarpoor M, Poureisa M, Daghighi MH. Comparison of maximum signal intensity of contrast agent on T1 weighted images using spin-echo, fast spin-echo and inversion recovery sequences. Iran J Radiol. 2013; 10: 27-32.
35. Saharkhiz H, Gharehaghaji N, Nazarpoor M, Mesbahi A, Pourissa M. The effect of inversion time on the relationship between iron oxide nanoparticles concentration and signal intensity in T1-weighted MR Images. Iran J Radiol. 2014; 11: e12667-e12667.
36. Nazarpoor M. Non-uniformity of clinical head, head and neck, and body coils in Magnetic Resonance Imaging (MRI). Iran J Med Phys. 2014; 11: 322-327.
37. McRobbie DW, Moore EA, Graves MJ, Prince MR. MRI from protons to pictures, Cambridge, 2006.
38. Chambon C, Clement O, Blanche AL, Shchouman-claeys E, Frija G. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. J Magn Reson Imaging. 1993; 11: 509-519.
39. Canet E, Revel D. Superparamagnetic iron oxide particles and positive enhancement for myocardial perfusion studies assessed by subsecond TI-weighted MRI. J Magn Reson Imaging. 1993; 11: 1139-1145.
)